These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33307909)

  • 1. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases.
    Harbi MH; Smith CW; Nicolson PLR; Watson SP; Thomas MR
    Platelets; 2021 Jan; 32(1):29-41. PubMed ID: 33307909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
    Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
    J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.
    Manne BK; Badolia R; Dangelmaier C; Eble JA; Ellmeier W; Kahn M; Kunapuli SP
    J Biol Chem; 2015 May; 290(18):11557-68. PubMed ID: 25767114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice.
    Bender M; May F; Lorenz V; Thielmann I; Hagedorn I; Finney BA; Vögtle T; Remer K; Braun A; Bösl M; Watson SP; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2013 May; 33(5):926-34. PubMed ID: 23448972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional significance of the platelet immune receptors GPVI and CLEC-2.
    Rayes J; Watson SP; Nieswandt B
    J Clin Invest; 2019 Jan; 129(1):12-23. PubMed ID: 30601137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.
    Hardy AT; Palma-Barqueros V; Watson SK; Malcor JD; Eble JA; Gardiner EE; Blanco JE; Guijarro-Campillo R; Delgado JL; Lozano ML; Teruel-Montoya R; Vicente V; Watson SP; Rivera J; Ferrer-Marín F
    Thromb Haemost; 2018 Jun; 118(6):1009-1020. PubMed ID: 29695020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose Btk inhibitors selectively block platelet activation by CLEC-2.
    Nicolson PLR; Nock SH; Hinds J; Garcia-Quintanilla L; Smith CW; Campos J; Brill A; Pike JA; Khan AO; Poulter NS; Kavanagh DM; Watson S; Watson CN; Clifford H; Huissoon AP; Pollitt AY; Eble JA; Pratt G; Watson SP; Hughes CE
    Haematologica; 2021 Jan; 106(1):208-219. PubMed ID: 31949019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the GPVI inhibitors losartan and honokiol.
    Onselaer MB; Nagy M; Pallini C; Pike JA; Perrella G; Quintanilla LG; Eble JA; Poulter NS; Heemskerk JWM; Watson SP
    Platelets; 2020; 31(2):187-197. PubMed ID: 30849265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein VI - novel target in antiplatelet medication.
    Borst O; Gawaz M
    Pharmacol Ther; 2021 Jan; 217():107630. PubMed ID: 32681846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel interactions in platelet biology: CLEC-2/podoplanin and laminin/GPVI.
    Ozaki Y; Suzuki-Inoue K; Inoue O
    J Thromb Haemost; 2009 Jul; 7 Suppl 1():191-4. PubMed ID: 19630798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands.
    Alshehri OM; Montague S; Watson S; Carter P; Sarker N; Manne BK; Miller JL; Herr AB; Pollitt AY; O'Callaghan CA; Kunapuli S; Arman M; Hughes CE; Watson SP
    Biochem J; 2015 Jun; 468(3):459-73. PubMed ID: 25849538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPVI and CLEC-2 in hemostasis and vascular integrity.
    Watson SP; Herbert JM; Pollitt AY
    J Thromb Haemost; 2010 Jul; 8(7):1456-67. PubMed ID: 20345705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
    Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo.
    Alshahrani MM; Yang E; Yip J; Ghanem SS; Abdallah SL; deAngelis AM; O'Malley CJ; Moheimani F; Najjar SM; Jackson DE
    Blood; 2014 Oct; 124(15):2431-41. PubMed ID: 25085348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke.
    Induruwa I; Jung SM; Warburton EA
    Int J Stroke; 2016 Aug; 11(6):618-25. PubMed ID: 27312676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease.
    Slater A; Khattak S; Thomas MR
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):465-473. PubMed ID: 38453424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ.
    Oishi S; Tsukiji N; Otake S; Oishi N; Sasaki T; Shirai T; Yoshikawa Y; Takano K; Shinmori H; Inukai T; Kondo T; Suzuki-Inoue K
    Blood Adv; 2021 Apr; 5(7):2017-2026. PubMed ID: 33843987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances of Studies on Platelet GPVI as Antithrombotic Target -Review].
    Li P; Qiao JL; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):264-269. PubMed ID: 28245414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
    Harbi MH; Smith CW; Alenazy FO; Nicolson PLR; Tiwari A; Watson SP; Thomas MR
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.